HOHeidi Gytz Olesen

Heidi Gytz Olesen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Heidi Gytz Olesen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Structure–function analysis of empasiprubart, a calcium- and pH-dependent clinical phase complement C2 blocking antibody

    by Laura Bracke, Heidi Gytz Olesen, Erwin Pannecoucke, Tim Delahaye, Emma K. Persson, Christophe Blanchetot, Hans de Haard, C. Erik Hack, Gregers Rom Andersen, Inge Van de Walle

    Empasiprubart (ARGX-117) is a humanized recycling antibody that prevents binding of C2 to C4b, blocking downstream classical and lectin pathways of complement activation. Empasiprubart binds to the CCP2 domain of complement component C2 in a calcium- and pH-dependent manner, leveraging physiological differences between blood and endosomal environments to facilitate the release and subsequent degradation of bound C2. The molecule incorporates Fc region mutations (H433K and N434F) that enhance its affinity for the neonatal Fc receptor (FcRn) under acidic endosomal conditions, thereby prolonging its in vivo half-life and supporting its recycling capacity. However, despite the earlier description of the complex structure, the molecular mechanism underlying these dependencies has remained elusive. Here, we further explored the crystal structure of the empasiprubart fragment antigen-binding (Fab) complexed to a C2 fragment, and provide a molecular rationale for its unique properties, while recognizing that not all contributing factors have been fully elucidated. Our observations indicate that the pH-dependent target release is rooted in a subtle intramolecular complementarity-determining region (CDR) destabilization, rather than direct modulation of the binding interface, and highlight the interplay between framework residues and CDRs. Collectively, our results not only lead to a better understanding of the mode of action of empasiprubart but also demonstrate the pivotal role of framework residues in the orchestration of antibody CDR function for non-trivial target binding.


  • Open Access

    Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring

    by Trine Amalie Fogh Gadeberg, Martin Høgholm Jørgensen, Heidi Gytz Olesen, Josefine Lorentzen, Seandean Lykke Harwood, Ana Viana Almeida, Marlene Uglebjerg Fruergaard, Rasmus Kjeldsen Jensen, Philipp Kanis, Henrik Pedersen, et al.

    The C3 protein is the central molecule within the complement system and undergoes pattern-recognition-dependent proteolytic activation to C3b in the presence of pathogens and damage-associated patterns. Spontaneous pattern-independent activation of C3 occurs via hydrolysis, resulting in C3(H 2 O). However, the structural details of C3 hydrolysis remain elusive. Here, we show that the conformation of the C3(H 2 O) analog, C3MA, in which the C3 thioester is broken by aminolysis is indistinguishable from C3b except for the 77-residue anaphylatoxin (ANA) domain. In contrast, the reaction intermediate C3* formed during C3 adopts a dynamic conformation dramatically different from both C3 and C3MA/C3b. In C3*, unlocking of the macroglobulin (MG) 3 domain creates a large opening in the MG-ring through which the ANA domain translocates. In support of this mechanism, C3MA formation is inhibited by an MG3/MG4-interface-specific nanobody and prevented by linking the ANA domain to the C3 β-chain. Our study reveals an unexpected dynamic behavior of C3 where an exceptional conformational change allows the translocation of an entire domain through a large dynamic opening. These results form the basis for elucidation of the in vivo contribution of C3 hydrolysis to complement activation and offer a rational approach for modulation of C3(H 2 O) with the potential for preventing complement activation caused by intravascular hemolysis and surface contacts.


  • Trypanosoma brucei Invariant Surface gp65 Inhibits the Alternative Pathway of Complement by Accelerating C3b Degradation

    by Josefine Lorentzen, Heidi G. Olesen, Annette G. Hansen, Steffen Thiel, Svend Birkelund, Christian B. F. Andersen, Gregers R. Andersen

    Trypanosomes are known to activate the complement system on their surface, but they control the cascade in a manner such that the cascade does not progress into the terminal pathway. It was recently reported that the invariant surface glycoprotein ISG65 from Trypanosoma brucei interacts reversibly with complement C3 and its degradation products, but the molecular mechanism by which ISG65 interferes with complement activation remains unknown. In this study, we show that ISG65 does not interfere directly with the assembly or activity of the two C3 convertases. However, ISG65 acts as a potent inhibitor of C3 deposition through the alternative pathway in human and murine serum. Degradation assays demonstrate that ISG65 stimulates the C3b to iC3b converting activity of complement factor I in the presence of the cofactors factor H or complement receptor 1. A structure-based model suggests that ISG65 promotes a C3b conformation susceptible to degradation or directly bridges factor I and C3b without contact with the cofactor. In addition, ISG65 is observed to form a stable ternary complex with the ligand binding domain of complement receptor 3 and iC3b. Our data suggest that ISG65 supports trypanosome complement evasion by accelerating the conversion of C3b to iC3b through a unique mechanism.


  • Open Access

    Nanobody‐mediated complement activation to kill HIV‐infected cells

    by Maria Lange Pedersen, Dennis Vestergaard Pedersen, Mikael Becher Lykkegaard Winkler, Heidi Gytz Olesen, Ole Schmeltz Søgaard, Lars Østergaard, Nick Stub Laursen, Anna Halling Folkmar Rahimic, Martin Tolstrup

    The complement system which is part of the innate immune response against invading pathogens represents a powerful mechanism for killing of infected cells. Utilizing direct complement recruitment for complement‐mediated elimination of HIV‐1‐infected cells is underexplored. We developed a novel therapeutic modality to direct complement activity to the surface of HIV‐1‐infected cells. This bispecific complement engager (BiCE) is comprised of a nanobody recruiting the complement‐initiating protein C1q, and single‐chain variable fragments of broadly neutralizing antibodies (bNAbs) targeting the HIV‐1 envelope (Env) protein. Here, we show that two anti‐HIV BiCEs targeting the V3 loop and the CD4 binding site, respectively, increase C3 deposition and mediate complement‐dependent cytotoxicity (CDC) of HIV‐1 Env‐expressing Raji cells. Furthermore, anti‐HIV BiCEs trigger complement activation on primary CD4 T cells infected with laboratory‐adapted HIV‐1 strain and facilitates elimination of HIV‐1‐infected cells over time. In summary, we present a novel approach to direct complement deposition to the surface of HIV‐1‐infected cells leading to complement‐mediated killing of these cells.


  • Open Access

    Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex

    by Heidi Gytz Olesen, Iliana Michailidou, Wioleta M. Zelek, Jeroen Vreijling, Patrick Ruizendaal, Ferry de Klein, J. Arnoud Marquart, Thomas B. Kuipers, Hailiang Mei, Yuchun Zhang, et al.

    Damage and disease of nerves activates the complement system. We demonstrated that activation of the terminal pathway of the complement system leads to the formation of the membrane attack complex (MAC) and delays regeneration in the peripheral nervous system. Animals deficient in the complement component C6 showed improved recovery after neuronal trauma. Thus, inhibitors of the MAC might be of therapeutic use in neurological disease. Here, we describe the development, structure, mode of action, and properties of a novel therapeutic monoclonal antibody, CP010, against C6 that prevents formation of the MAC in vivo. The monoclonal antibody is humanized and specific for C6 and binds to an epitope in the FIM1-2 domain of human and primate C6 with sub-nanomolar affinity. Using biophysical and structural studies, we show that the anti-C6 antibody prevents the interaction between C6 and C5/C5b by blocking the C6 FIM1-2:C5 C345c axis. Systemic administration of the anti-C6 mAb caused complete depletion of free C6 in circulation in transgenic rats expressing human C6 and thereby inhibited MAC formation. The antibody prevented disease in experimental autoimmune myasthenia gravis and ameliorated relapse in chronic relapsing experimental autoimmune encephalomyelitis in human C6 transgenic rats. CP010 is a promising complement C6 inhibitor that prevents MAC formation. Systemic administration of this C6 monoclonal antibody has therapeutic potential in the treatment of neuronal disease.


  • A Complement C3–Specific Nanobody for Modulation of the Alternative Cascade Identifies the C-Terminal Domain of C3b as Functional in C5 Convertase Activity

    by Henrik Pedersen, Rasmus K. Jensen, Jens Magnus B. Jensen, Rachel Fox, Dennis V. Pedersen, Heidi G. Olesen, Annette G. Hansen, Dorte Christiansen, Sofia M. M. Mazarakis, Neal Lojek, et al.

    The complement system is an intricate cascade of the innate immune system and plays a key role in microbial defense, inflammation, organ development, and tissue regeneration. There is increasing interest in developing complement regulatory and inhibitory agents to treat complement dysfunction. In this study, we describe the nanobody hC3Nb3, which is specific for the C-terminal C345c domain of human and mouse complement component C3/C3b/C3c and potently inhibits C3 cleavage by the alternative pathway. A high-resolution structure of the hC3Nb3–C345c complex explains how the nanobody blocks proconvertase assembly. Surprisingly, although the nanobody does not affect classical pathway–mediated C3 cleavage, hC3Nb3 inhibits classical pathway–driven hemolysis, suggesting that the C-terminal domain of C3b has an important function in classical pathway C5 convertase activity. The hC3Nb3 nanobody binds C3 with low nanomolar affinity in an SDS-resistant complex, and the nanobody is demonstrated to be a powerful reagent for C3 detection in immunohistochemistry and flow cytometry. Overall, the hC3Nb3 nanobody represents a potent inhibitor of both the alternative pathway and the terminal pathway, with possible applications in complement research, diagnostics, and therapeutics.